// App-Quantinova.ai

1230 : BGB-283: a novel RAF Dimer inhibitor, displays potent antitumor activity in HCC patient derived xenograft models

Researchers

Presenter

  • Zhiyu Tang

Principal Investigators

  • Yong Liu

  • Beibei Jiang

  • Yajuan Gao

  • Wenfeng Gong

  • Xing Wang

  • Dan Su

  • Fenglong Yu

  • Ye Liu

  • Min Wei

  • Lai Wang

Medical Centers

  • BeiGene, Beijing, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

  • Solid malignancies

Biomarkers

  • Mitogen-activated protein kinase

  • Kinase Insert Domain Receptor

  • Vascular endothelial growth factor A

Drug/Treatment

  • Sorafenib

  • BGB-283

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved